Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4N2JV
|
|||
| Drug Name |
PRX002
|
|||
| Synonyms |
Prasinezumab
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-10: F02.3, G20; ICD-9: 332] | Phase 2 | [1] | |
| Company |
ProThena; Roche
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Synuclein alpha (SNCA) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Alzheimer's disease | |||
| Parkinson's disease | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| Panther Pathway | Parkinson disease | |||
| Pathway Interaction Database | Alpha-synuclein signaling | |||
| Reactome | Amyloid formation | |||
| WikiPathways | Ectoderm Differentiation | |||
| Parkinsons Disease Pathway | ||||
| Parkin-Ubiquitin Proteasomal System pathway | ||||
| Alzheimers Disease | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03100149) A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA). U.S. National Institutes of Health. | |||
| REF 2 | Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-alpha-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 Oct 1;75(10):1206-1214. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.